Non-profit invests $4.2 million in novel approach to Alzheimer's

14 December 2023

brain_alzheimer-s_neurology_neuroscience_big

Swiss neurology specialist GliaPharm has announced a new investment of $4.2 million for its lead program in Alzheimer’s disease.

The money has been put forward by the Alzheimer’s Drug Discovery Foundation (ADDF), a non-profit organization working on promoting drug discovery and development in this area.

It will enable lead compound GP-119 - a novel orally active small molecule that acts on brain energy metabolism - to be brought into the clinical stage.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK